Phase 2
Completed N=294
Efficacy Study in Patients With Acne Vulgaris.
Source: ClinicalTrials.gov NCT02935036 ↗Enrolled (actual)
294
Serious AEs
0.4%
Results posted
Sep 2018
Primary outcomePrimary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts on the Face — -60.84; -62.17 percentage change in lesion counts — p=0.5947
Summary
Safety and efficacy study in patients with acne vulgaris
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts on the Face |
-60.84; -62.17 | 0.5947 |
| PRIMARY Percent Change From Baseline to Week 12 in the Non-inflammatory (Open and Closed Comedones) Lesion Counts on the Face |
-49.91; -52.67 | 0.2912 |
| PRIMARY The Percentage of Subjects With a Clinical Response (IGA) of "Success" at Week 12 on the Face. |
13.0; 10.6 | 0.6920 |
Eligibility Criteria
Inclusion Criteria
- Healthy male or non pregnant female aged ≥ 9 years with a clinical diagnosis of acne vulgaris
Exclusion Criteria
- Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.
Data sourced from ClinicalTrials.gov (NCT02935036). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.